Skip to main content

Table 2 League charts of observational studies. League charts of observational studies intercomparing the risks of Alzheimer’s disease among different anti-diabetic agents and placebo

From: Anti-diabetic agents and the risks of dementia in patients with type 2 diabetes: a systematic review and network meta-analysis of observational studies and randomized controlled trials

Non-users

0.94 (0.78,1.13)

1.53 (0.92,2.54)

0.82 (0.67,1.01)

0.94 (0.79,1.12)

0.43 (0.30,0.62)

0.54 (0.30,0.96)

0.73 (0.57,0.93)

0.71 (0.18,2.86)

1.07 (0.89,1.28)

Metformin

1.63 (0.95,2.80)

0.88 (0.71,1.08)

1.01 (0.87,1.16)

0.46 (0.31,0.68)

0.57 (0.32,1.04)

0.78 (0.59,1.02)

0.76 (0.19,3.09)

0.65 (0.39,1.09)

0.61 (0.36,1.05)

Insulin

0.54 (0.31,0.93)

0.62 (0.36,1.05)

0.28 (0.15,0.53)

0.35 (0.16,0.76)

0.48 (0.27,0.84)

0.46 (0.11,2.04)

1.22 (0.99,1.50)

1.14 (0.92,1.41)

1.86 (1.07,3.22)

TZD

1.15 (0.91,1.44)

0.52 (0.34,0.79)

0.65 (0.36,1.20)

0.88 (0.65,1.20)

0.86 (0.21,3.53)

1.06 (0.89,1.26)

0.99 (0.86,1.15)

1.62 (0.95,2.77)

0.87 (0.69,1.10)

Sulfonylureas

0.46 (0.31,0.66)

0.57 (0.32,1.02)

0.77 (0.60,0.98)

0.75 (0.18,3.07)

2.33 (1.61,3.37)

2.18 (1.48,3.22)

3.56 (1.90,6.67)

1.91 (1.26,2.90)

2.19 (1.51,3.19)

SGLT-2i

1.25 (0.80,1.95)

1.69 (1.28,2.24)

1.65 (0.39,6.99)

1.86 (1.04,3.32)

1.74 (0.96,3.15)

2.85 (1.32,6.15)

1.53 (0.83,2.82)

1.75 (0.98,3.14)

0.80 (0.51,1.25)

GLP-1RA

1.35 (0.80,2.30)

1.32 (0.29,5.98)

1.37 (1.07,1.76)

1.29 (0.98,1.68)

2.10 (1.20,3.70)

1.13 (0.83,1.54)

1.30 (1.02,1.65)

0.59 (0.45,0.78)

0.74 (0.44,1.25)

DPP-4i

0.98 (0.24,4.02)

1.41 (0.35,5.67)

1.32 (0.32,5.38)

2.15 (0.49,9.49)

1.16 (0.28,4.74)

1.33 (0.33,5.41)

0.61 (0.14,2.56)

0.76 (0.17,3.42)

1.02 (0.25,4.22)

AGI